Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Bladder Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 59 articles:
HTML format



Single Articles


    June 2020
  1. WEINER AB, Pham MN, Isaacson DS, Ko OS, et al
    Predictors of use and overall survival for patients undergoing metastasectomy for bladder cancer in a national cohort.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14288.
    PubMed     Abstract available


  2. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
    Int J Urol. 2020 Jun 21. doi: 10.1111/iju.14281.
    PubMed     Abstract available


  3. SHIN T
    Editorial Comment from Dr Shin to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14282.
    PubMed    


  4. ADOMI S, Fujita K, Yoshimura K, Uemura H, et al
    Editorial Comment from Dr Adomi et al. to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14284.
    PubMed    


    May 2020
  5. OKITA K, Hatakeyama S, Momota M, Soma O, et al
    Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 May 25. doi: 10.1111/iju.14263.
    PubMed     Abstract available


    March 2020
  6. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.
    Int J Urol. 2020 Mar 14. doi: 10.1111/iju.14210.
    PubMed     Abstract available


    February 2020
  7. ABE T
    Editorial Comment from Dr Abe to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14193.
    PubMed    


  8. TANAKA H, Fujii Y
    Editorial Comment from Dr Tanaka and Dr Fujii to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14194.
    PubMed    


    January 2020
  9. TANAKA H, Fukushima H, Kijima T, Nakamura Y, et al
    Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jan 19. doi: 10.1111/iju.14179.
    PubMed     Abstract available


  10. KANNO T, Inoue T, Ito K, Okumura K, et al
    Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Jan 16. doi: 10.1111/iju.14182.
    PubMed     Abstract available


    December 2019
  11. KIKUCHI E, Hayakawa N, Fukumoto K, Shigeta K, et al
    Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Int J Urol. 2019 Dec 3. doi: 10.1111/iju.14153.
    PubMed     Abstract available


    October 2019
  12. FUKUHARA H
    Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14124.
    PubMed    


  13. MATSUMOTO H
    Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14131.
    PubMed    


    September 2019
  14. NOHARA T, Kato Y, Nakano T, Nakagawa T, et al
    Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14099.
    PubMed     Abstract available


  15. CHOO SH, Nishiyama H, Kitamura H, Chen CH, et al
    Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14105.
    PubMed     Abstract available


    August 2019
  16. YOSHIDA T, Kates M, Fujita K, Bivalacqua TJ, et al
    Predictive biomarkers for drug response in bladder cancer.
    Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082.
    PubMed     Abstract available


    July 2019
  17. FUJIMURA T
    Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14076.
    PubMed     Abstract available


  18. TEISHIMA J, Matsubara A
    Editorial Comment to Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14086.
    PubMed    


  19. KOJIMA T
    Editorial Comment from Dr Kojima to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, inductio
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14074.
    PubMed    


  20. KOBAYASHI T
    Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induc
    Int J Urol. 2019 Jul 21. doi: 10.1111/iju.14075.
    PubMed    


  21. OSAWA T, Wei JT, Abe T, Kako Y, et al
    Development of the Japanese version of the health-related quality of life questionnaire for bladder cancer patients using the Bladder Cancer Index: A pilot study.
    Int J Urol. 2019 Jul 16. doi: 10.1111/iju.14073.
    PubMed    


  22. TOIDE M, Yokoyama M, Fujiwara M, Kijima T, et al
    Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cyst
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14054.
    PubMed    


    March 2019
  23. NAKAYAMA M, Ito Y, Hatano K, Nakai Y, et al
    Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.
    Int J Urol. 2019 Mar 27. doi: 10.1111/iju.13955.
    PubMed     Abstract available


  24. LEE A, Lee HJ, Huang HH, Ho H, et al
    Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13913.
    PubMed     Abstract available


  25. ZACHOS I
    Editorial Comment to Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13929.
    PubMed    


    February 2019
  26. YASUI M, Kawahara T, Takamoto D, Izumi K, et al
    Distribution of androgen receptor expression in the urinary bladder.
    Int J Urol. 2019;26:305-306.
    PubMed    


    January 2019
  27. KOIE T, Ohyama C, Makiyama K, Shimazui T, et al
    Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13900.
    PubMed     Abstract available


  28. TEISHIMA J, Matsubara A
    Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13906.
    PubMed    


  29. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2019 Jan 22. doi: 10.1111/iju.13893.
    PubMed     Abstract available


    December 2018
  30. HASHIMOTO T
    Editorial Comment from Dr Hashimoto to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 16. doi: 10.1111/iju.13889.
    PubMed    


  31. NAKATA W, Yamamichi G, Tsujimura G, Tsujimoto Y, et al
    Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 2. doi: 10.1111/iju.13880.
    PubMed    


    November 2018
  32. MIYAKE M, Nakai Y, Hori S, Morizawa Y, et al
    Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2018 Nov 18. doi: 10.1111/iju.13856.
    PubMed    


    October 2018
  33. ADELOYE D, Harhay MO, Ayepola OO, Dos Santos JP, et al
    Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis.
    Int J Urol. 2018 Oct 21. doi: 10.1111/iju.13824.
    PubMed     Abstract available


  34. MIYAKE M, Hori S, Owari T, Morizawa Y, et al
    Animal model of local tumor recurrence after resection using the murine MBT2 bladder cancer cell line in syngeneic C3H mice.
    Int J Urol. 2018 Oct 16. doi: 10.1111/iju.13834.
    PubMed    


    July 2018
  35. OHTAKA M, Kawahara T, Ishiguro Y, Sharma M, et al
    Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.
    Int J Urol. 2018 Jul 24. doi: 10.1111/iju.13756.
    PubMed    


  36. ZHANG D, Zhou C, Li Y, Gao L, et al
    Amyloid precursor protein is overexpressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13726.
    PubMed     Abstract available


  37. NAKAI Y, Inoue K, Tsuzuki T, Shimamoto T, et al
    Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13718.
    PubMed     Abstract available


  38. YANG J, Zhang P, Zhou H, Feng S, et al
    Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13719.
    PubMed    


    March 2018
  39. MIYAZAKI J, Onozawa M, Takaoka E, Yano I, et al
    Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer.
    Int J Urol. 2018 Mar 5. doi: 10.1111/iju.13538.
    PubMed     Abstract available


  40. TATSUGAMI K
    Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2018;25:218-219.
    PubMed    


    February 2018
  41. OTTO W, van Rhijn BW, Breyer J, Bertz S, et al
    Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer.
    Int J Urol. 2018 Feb 22. doi: 10.1111/iju.13532.
    PubMed     Abstract available


    December 2017
  42. FUJII Y
    Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Dec 16. doi: 10.1111/iju.13509.
    PubMed     Abstract available


  43. OHNO Y
    Editorial Comment to High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Dec 7. doi: 10.1111/iju.13506.
    PubMed    


    November 2017
  44. YANG X, Shi L, Yi C, Yang Y, et al
    Astrocyte elevated gene-1 promotes invasion and epithelial-mesenchymal transition in bladder cancer cells through activation of signal transducer and activator of transcription 3.
    Int J Urol. 2017 Nov 8. doi: 10.1111/iju.13486.
    PubMed     Abstract available


  45. TAN YG, Eu EWC, Huang HH, Lau WKO, et al
    High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Nov 1. doi: 10.1111/iju.13480.
    PubMed     Abstract available


    July 2017
  46. SALUJA M, Gilling P
    Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Jul 25. doi: 10.1111/iju.13410.
    PubMed     Abstract available


  47. KOBATAKE K, Hayashi T, Black PC, Goto K, et al
    Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13389.
    PubMed     Abstract available


  48. NASELLI A
    Editorial Comment to Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 21. doi: 10.1111/iju.13402.
    PubMed    


    March 2017
  49. SHIMIZU F, Muto S, Taguri M, Ieda T, et al
    Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Int J Urol. 2017 Mar 9. doi: 10.1111/iju.13324.
    PubMed     Abstract available


    February 2017
  50. INOUE K
    5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
    Int J Urol. 2017;24:97-101.
    PubMed     Abstract available


    January 2017
  51. ALIMI Q, Verhoest G, Kammerer-Jacquet SF, Mathieu R, et al
    Response to Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13290.
    PubMed    


  52. MATSUMURA N, Nakamura Y, Kohjimoto Y, Nishizawa S, et al
    Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
    Int J Urol. 2017 Jan 9. doi: 10.1111/iju.13274.
    PubMed     Abstract available


    December 2016
  53. ALEVIZOPOULOS A, Tyritzis S, Leotsakos I, Anastasopoulou I, et al
    Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13271.
    PubMed     Abstract available


  54. BESIROGLU H
    Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2016 Dec 1. doi: 10.1111/iju.13269.
    PubMed    


    November 2016
  55. REIS LO
    Editorial Comment to Orthotopic mouse model of renal pelvic cancer using a human bladder cancer cell line.
    Int J Urol. 2016;23:963.
    PubMed    


    October 2016
  56. VIDAL A, Arnold N, Vartolomei MD, Kiss B, et al
    Oncological and functional outcomes of postoperative total parenteral nutrition after radical cystectomy in bladder cancer patients: A single-center randomized trial.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13228.
    PubMed     Abstract available


  57. HERMANS TJ, van de Putte EE, Horenblas S, van Rhijn BW, et al
    Extended pelvic lymph node dissection at radical cystectomy for bladder cancer improves survival: Results of a nationwide population-based study.
    Int J Urol. 2016 Oct 4. doi: 10.1111/iju.13227.
    PubMed    


    April 2016
  58. DAL MORO F, Zattoni F
    Lighting from the urethral cystoscope side: A novel technique to safely manage bowel division during intracorporeal robotic urinary diversion.
    Int J Urol. 2016;23:344-5.
    PubMed    


  59. JINZAKI M, Kikuchi E, Akita H, Sugiura H, et al
    Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma.
    Int J Urol. 2016;23:284-98.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: